MX2023006704A - Composiciones dsg2 y metodos para el tratamiento de covid-19. - Google Patents

Composiciones dsg2 y metodos para el tratamiento de covid-19.

Info

Publication number
MX2023006704A
MX2023006704A MX2023006704A MX2023006704A MX2023006704A MX 2023006704 A MX2023006704 A MX 2023006704A MX 2023006704 A MX2023006704 A MX 2023006704A MX 2023006704 A MX2023006704 A MX 2023006704A MX 2023006704 A MX2023006704 A MX 2023006704A
Authority
MX
Mexico
Prior art keywords
methods
compositions
covid
treatment
dsg2
Prior art date
Application number
MX2023006704A
Other languages
English (en)
Spanish (es)
Inventor
Shi Yin Foo
Ryan Edward Tyler
Original Assignee
Arvada Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arvada Therapeutics Inc filed Critical Arvada Therapeutics Inc
Publication of MX2023006704A publication Critical patent/MX2023006704A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MX2023006704A 2020-12-15 2021-12-15 Composiciones dsg2 y metodos para el tratamiento de covid-19. MX2023006704A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063125583P 2020-12-15 2020-12-15
US202163274715P 2021-11-02 2021-11-02
PCT/US2021/063433 WO2022132854A1 (en) 2020-12-15 2021-12-15 Dsg2 compositions and methods for the treatment of covid-19

Publications (1)

Publication Number Publication Date
MX2023006704A true MX2023006704A (es) 2023-06-20

Family

ID=79425717

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023006704A MX2023006704A (es) 2020-12-15 2021-12-15 Composiciones dsg2 y metodos para el tratamiento de covid-19.

Country Status (9)

Country Link
EP (1) EP4263588A1 (https=)
JP (1) JP2024500250A (https=)
KR (1) KR20230120141A (https=)
AU (1) AU2021400845A1 (https=)
CA (1) CA3202364A1 (https=)
IL (1) IL303444A (https=)
MX (1) MX2023006704A (https=)
TW (1) TW202237634A (https=)
WO (1) WO2022132854A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2024005327A (es) * 2021-11-02 2024-05-21 Arvada Therapeutics Inc Composiciones y metodos de dsg2.
CN116458893A (zh) * 2023-04-19 2023-07-21 电子科技大学 一种covid-19后心肌缺血的早期筛查方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100316347B1 (ko) 1998-09-15 2002-08-27 한미약품(주) 대장균엔테로톡신ⅱ신호펩티드의변형체와인체성장호르몬의융합단백질을발현하는재조합미생물및그를이용한인체성장호르몬의제조방법
DE10057397A1 (de) 2000-11-18 2002-05-23 Hella Kg Hueck & Co Vorrichtung zur Ölstandsmessung
US20100303723A1 (en) * 2006-11-20 2010-12-02 Massachusetts Institute Of Technology Drug delivery systems using fc fragments
US20190353652A1 (en) * 2017-01-13 2019-11-21 The Hospital For Sick Children Method for Diagnosis of Arrhythmogenic Right Ventricular Cardiomyopathy

Also Published As

Publication number Publication date
WO2022132854A1 (en) 2022-06-23
JP2024500250A (ja) 2024-01-05
KR20230120141A (ko) 2023-08-16
AU2021400845A1 (en) 2023-07-13
CA3202364A1 (en) 2022-06-23
TW202237634A (zh) 2022-10-01
IL303444A (en) 2023-08-01
EP4263588A1 (en) 2023-10-25

Similar Documents

Publication Publication Date Title
ZA202109010B (en) Compounds and methods for the treatment of covid-19
MX2022001607A (es) Composiciones y metodos para tratar la psoriasis y la dermatitis atopica usando prevotella histicola.
PH12020551427A1 (en) Epinephrine spray formulations
GB201318761D0 (en) Compounds for the treatment of neuropsychiatric disorders
ZA202304965B (en) Combination therapy for treating cancer
EA202193111A1 (ru) Композиции и способы для лечения рака
MX2023001296A (es) Composiciones y metodos para tratar enfermedades y trastornos.
MX2023006704A (es) Composiciones dsg2 y metodos para el tratamiento de covid-19.
WO2024163641A3 (en) Formulations for treating cancer
WO2023097194A3 (en) Bicyclic therapeutic compounds and methods of use in the treatment of cancer
WO2024006292A3 (en) Methods of treating cancer
PH12022552489A1 (en) V delta1+ t cells for the treatment of myeloid malignancies
EP4591928A3 (en) Composition for the treatment of gastroesophageal reflux comprising hyaluronic acid
MX2022012001A (es) Tratamiento preventivo de la migra?a.
MX2022004785A (es) Metodos y composiciones para el tratamiento del sindrome de rett.
ZA202211253B (en) Compositions comprising 15-hepe for treating or preventing hematologic disorders, and/or related diseases
EA202193276A1 (ru) Способы лечения холангиокарциномы
MX2021011289A (es) Composiciones que comprenden moduladores de isoenzima m2 muscular de piruvato cinasa pkm2 y metodos de tratamiento que usan las mismas.
EP4335460A3 (en) Compositions and methods for treating granulomatosis with polyangiitis
EA202190751A1 (ru) Способы лечения миелопролиферативных расстройств
MX2023004881A (es) Inhibidores de pde9 para el tratamiento de insuficiencia cardíaca.
EP4620940A3 (en) Synthesis of (+)-cannabinoids and their therapeutic effects
MX2024010401A (es) Quiméricos dirigido a proteólisis (protac) de proteína de translocación del linfoma del tejido linfoide asociado a las mucosas 1 (malt1)
WO2020061067A8 (en) Compositions and methods for treating bone injury
MX2023009620A (es) Metodos terapeuticos.